MUMBAI, India, June 13 -- Intellectual Property India has published a patent application (202517051760 A) filed by Merck Patent Gmbh, Darmstadt, Germany, on May 29, for 'toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity.'
Inventor(s) include Shan, Min; Wakim, Jean; and Goutopoulos, Andreas.
The application for the patent was published on June 13, under issue no. 24/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to compounds that can specifically activate TLR7. The compounds of the invention are useful because they can stimulate innate immunity. The compounds of the invention can be used in the treatment of conditions including cancer, viral infections and skin lesions. The compounds can optionally be formulated for enhanced penetration following topical administration, said composition preferably initiating a local specific inflammatory cytokine response while limiting undesirable erythema and other inflammatory reactions. The invention also relates to pharmaceutical compositions comprising the compound of the invention and preferably an additional compound such as imiquimod and/or resiquimod (R848). The invention also relates to a composition comprising a compound of the invention and to a compound for use as a medicament. Other aspects, embodiments, advantages and applications of the invention will become clear from the further description herein."
The patent application was internationally filed on Nov. 08, 2023, under International application No.PCT/EP2023/081105.
Disclaimer: Curated by HT Syndication.
